Bausch Health Companies (BHC) EBITDA (2009 - 2026)

Bausch Health Companies has disclosed EBITDA across 18 years of filings, most recently posting -$950.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$950.0 million, down 444.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $587.0 million (down 61.91% YoY), and the FY2025 annual result was $1.8 billion, up 17.27% from the prior year.
• EBITDA came in at -$950.0 million for Q1 2026 at Bausch Health Companies, down from $474.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $619.0 million in Q3 2025 to a low of -$950.0 million in Q1 2026.
• The 5-year median for EBITDA is $285.0 million (2022), against an average of $225.1 million.
• Across the five-year window, EBITDA surged 2171.43% in 2024 and plunged 444.2% in 2026, its largest moves.
• Bausch Health Companies' EBITDA stood at -$236.0 million in 2022, then surged by 253.39% to $362.0 million in 2023, then surged by 54.14% to $558.0 million in 2024, then retreated by 15.05% to $474.0 million in 2025, then plunged by 300.42% to -$950.0 million in 2026.
• The last three EBITDA figures came in at -$950.0 million (Q1 2026), $474.0 million (Q4 2025), and $619.0 million (Q3 2025), per Business Quant data.